Zaiding Pharmaceutical: Ruiputinib has been approved by the state for the treatment of ROS1 positive non-small cell lung cancer patients
股海静观陶
发表于 2024-5-13 09:44:09
1311
0
0
Southern Finance and Economics, May 13 (Xinhua) - Zaiding Pharmaceutical Hong Kong Stock Exchange announced that the National Medical Products Administration of China has approved the use of reprotinib for the treatment of ROS1 positive non-small cell lung cancer patients.
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- Pfizer Besponsa has been approved by the FDA for the treatment of pediatric patients
- The latest research: Wegovy is also effective for patients with diabetes and heart failure
- Xiaomo bearish US stock market earnings season: Positive sentiment has been digested ahead of schedule, with most companies expecting a decline in profits
- Positive news keeps rising in major global markets, with multiple indices reaching historic highs!
- AstraZeneca lung cancer targeted drug Teresa has been approved for new indications in China
- American brain computer company pioneers: Empowering patients with communication skills through OpenAI models
- Baidu Health Platform has attracted over 300000 doctors to join and serve over 210 million patients
- Incidence rate of lung cancer death in women is higher than that in men
- AstraZeneca Imfinzi approved by FDA for postoperative adjuvant therapy in non-small cell lung cancer patients
- Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
